Alveolar Macrophages Inhibit Retrovirus-Mediated Gene Transfer to Airway Epithelia
- 10 June 1997
- journal article
- research article
- Published by Mary Ann Liebert Inc in Human Gene Therapy
- Vol. 8 (9) , 1087-1093
- https://doi.org/10.1089/hum.1997.8.9-1087
Abstract
Gene transfer with integrating vectors such as recombinant retrovirus has the potential to correct inherited lung diseases permanently. As a gene therapy target, the pulmonary epithelium presents several challenges to vector delivery in vivo. Many of the host defenses that have evolved to prevent infection from inhaled bacteria or viruses represent potential barriers to gene transfer to the lung. We performed in vitro studies to determine whether two components of the innate immune system of the lung, airway surface fluid and alveolar macrophages, inhibit retroviral gene transfer to airway epithelia. Human alveolar macrophages obtained by bronchoalveolar lavage from normal subjects were left untreated or activated with lipopolysaccharide (LPS) for 3 hr in the presence of subconfluent human bronchial epithelial cells (HBE); then 4 × 105 cfu DA-luciferase retrovirus was added. Three days after infection, luciferase activity was measured in cell lysates. When the epithelial cells were co-cultured with LPS-activated macrophages, retroviral gene transfer to HBE cells was reduced by ~60%. Nonactivated macrophages decreased the transfection to ~55% of control values. In control experiments with either activated or inactivated macrophages but without epithelia, no luciferase activity was detected, suggesting that terminally differentiated alveolar macrophages are not infected by the recombinant retrovirus. Pretreatment of alveolar macrophages with dexamethasone restored gene transfer to ~60% of control values. In contrast, incubation of retrovirus with airway surface fluid had no inhibitory effect on gene transfer. These experiments document that AM inhibit retrovirus-mediated gene transfer to airway epithelia in vitro, and may represent a barrier to retroviral gene transfer in vivo. These barriers may be overcome, at least partially, with pharmacological agents. Using in vitro co-culture studies, we present evidence that human alveolar macrophages inhibit gene transfer to airway epithelia by amphotropic enveloped retrovirus. The inhibitory effect was greater with activated macrophages and was partially reversed by pretreatment of the macrophages with dexamethasone. In contrast, airway surface fluid had no inhibitory effect on gene transfer. These findings have implications for gene transfer to the lung and suggest barriers that may be clinically important and strategies that may help overcome them.Keywords
This publication has 25 references indexed in Scilit:
- Hepatocytes corrected by gene therapy are selected in vivo in a murine model of hereditary tyrosinaemia type INature Genetics, 1996
- Pulmonary Inflammation Induced by Incomplete or Inactivated Adenoviral ParticlesHuman Gene Therapy, 1995
- MIF as a glucocorticoid-induced modulator of cytokine productionNature, 1995
- Macrophage-like RAW 264 cell line and time-resolved fluoroimmunoassay (TRFIA) as tools in screening drug effects on cytokine secretionInternational Journal of Immunopharmacology, 1995
- Modulation of the Antilisterial Activity of Human Blood-Derived Macrophages by Activating and Deactivating CytokinesJournal of Interferon & Cytokine Research, 1995
- Cytotoxic T-lymphocyte induction in asymptomatic HIV-1-infected patients immunized with Retrovector®-transduced autologous fibroblasts expressing HIV-1IIIB Env/Rev proteinsAIDS, 1995
- DefensinsPharmacology & Therapeutics, 1995
- Keratinocyte growth factor is a growth factor for type II pneumocytes in vivo.Journal of Clinical Investigation, 1994
- Tissue distribution of antileukoprotease and lysozyme in humans.Journal of Histochemistry & Cytochemistry, 1989
- Differential effects of glucocorticoid on expression of surfactant proteins in a human lung adenocarcinoma cell lineBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 1988